Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Spasticity - Market Insight, Epidemiology and Market Forecast - 2028

Published by DelveInsight Business Research LLP Product code 534852
Published Pre-Order Content info 100 Pages
Delivery time: 2-10 business days
Price
Back to Top
Spasticity - Market Insight, Epidemiology and Market Forecast - 2028
Published: Pre-Order Content info: 100 Pages
Description

DelveInsight's "Spasticity - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Spasticity epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Spasticity Understanding and Treatment Algorithm

The market report provides the overview of the Spasticity by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Spasticity Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Spasticity in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Spasticity Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Spasticity Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Spasticity market.

Spasticity Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Spasticity Report Insights

  • Patient Population in Spasticity
  • Therapeutic Approaches in Spasticity
  • Spasticity Pipeline Analysis
  • Spasticity Market Size and Trends
  • Spasticity Market Opportunities
  • Impact of upcoming Therapies in Spasticity

Spasticity Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Spasticity Report Assessment

  • Current Treatment Practices in Spasticity
  • Unmet Needs in Spasticity
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Spasticity market
  • Organize sales and marketing efforts by identifying the best opportunities for Spasticity market
  • To understand the future market competition in the Spasticity market.
Table of Contents
Product Code: DIMI0218

Table of Contents

1. Report Introduction

2. Spasticity Market Overview at a Glance

  • 2.1. Market Share Distribution of Spasticity in 2016
  • 2.2. Market Share Distribution of Spasticity in 2028

3. Disease Background and Overview: Spasticity

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Spasticity in 7MM
  • 4.3. Total Prevalent Patient Population of Spasticity in 7MM - By Countries

5. Epidemiology of Spasticity by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Spasticity
    • 5.1.3. Sub-Type Specific cases of the Spasticity *
    • 5.1.4. Sex- Specific Cases of the Spasticity *
    • 5.1.5. Diagnosed Cases of the Spasticity
    • 5.1.6. Treatable Cases of the Spasticity
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Spasticity
    • 5.4.3. Sub-Type Specific cases of the Spasticity *
    • 5.4.4. Sex- Specific Cases of the Spasticity *
    • 5.4.5. Diagnosed Cases of the Spasticity
    • 5.4.6. Treatable Cases of the Spasticity
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Spasticity
    • 5.5.3. Sub-Type Specific cases of the Spasticity *
    • 5.5.4. Sex- Specific Cases of the Spasticity *
    • 5.5.5. Diagnosed Cases of the Spasticity
    • 5.5.6. Treatable Cases of the Spasticity
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Spasticity
    • 5.6.3. Sub-Type Specific cases of the Spasticity *
    • 5.6.4. Sex- Specific Cases of the Spasticity *
    • 5.6.5. Diagnosed Cases of the Spasticity
    • 5.6.6. Treatable Cases of the Spasticity
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Spasticity
    • 5.7.3. Sub-Type Specific cases of the Spasticity *
    • 5.7.4. Sex- Specific Cases of the Spasticity *
    • 5.7.5. Diagnosed Cases of the Spasticity
    • 5.7.6. Treatable Cases of the Spasticity
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Spasticity
    • 5.8.3. Sub-Type Specific cases of the Spasticity *
    • 5.8.4. Sex- Specific Cases of the Spasticity *
    • 5.8.5. Diagnosed Cases of the Spasticity
    • 5.8.6. Treatable Cases of the Spasticity
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Spasticity
    • 5.9.3. Sub-Type Specific cases of the Spasticity *
    • 5.9.4. Sex- Specific Cases of the Spasticity *
    • 5.9.5. Diagnosed Cases of the Spasticity
    • 5.9.6. Treatable Cases of the Spasticity

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Spasticity

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Spasticity

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Spasticity : 7MM Market Analysis

  • 12.1. 7MM Market Size of Spasticity
  • 12.2. 7MM Percentage Share of drugs marketed for Spasticity
  • 12.3. 7MM Market Sales of Spasticity by Products

13. Spasticity : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Spasticity in United States
    • 13.1.2. Percentage Share of drugs marketed for Spasticity in United States
    • 13.1.3. Market Sales of Spasticity by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Spasticity in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Spasticity in Germany
      • 13.2.1.3. Market Sales of Spasticity by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Spasticity in France
      • 13.2.2.2. Percentage Share of drugs marketed for Spasticity in France
      • 13.2.2.3. Market Sales of Spasticity by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Spasticity in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Spasticity in Italy
      • 13.2.3.3. Market Sales of Spasticity by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Spasticity in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Spasticity in Spain
      • 13.2.4.3. Market Sales of Spasticity by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Spasticity in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Spasticity in United Kingdom
      • 13.2.5.3. Market Sales of Spasticity by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Spasticity in Japan
    • 13.3.2. Percentage Share of drugs marketed for Spasticity in Japan
    • 13.3.3. Market Sales of Spasticity by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Spasticity in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Spasticity in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Spasticity in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Spasticity in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Spasticity in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Spasticity in United States (2016-2028)
  • Table 7: Treatable Cases of the Spasticity in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Spasticity in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Spasticity in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Spasticity in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Spasticity in Germany (2016-2028)
  • Table 12: Treatable Cases of the Spasticity in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Spasticity in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Spasticity in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Spasticity in France (2016-2028)
  • Table 16: Diagnosed Cases of the Spasticity in France (2016-2028)
  • Table 17: Treatable Cases of the Spasticity in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Spasticity in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Spasticity in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Spasticity in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Spasticity in Italy (2016-2028)
  • Table 22: Treatable Cases of the Spasticity in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Spasticity in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Spasticity in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Spasticity in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Spasticity in Spain (2016-2028)
  • Table 27: Treatable Cases of the Spasticity in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Spasticity in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Spasticity in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Spasticity in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Spasticity in UK (2016-2028)
  • Table 32: Treatable Cases of the Spasticity in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Spasticity in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Spasticity in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Spasticity in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Spasticity in Japan (2016-2028)
  • Table 37: Treatable Cases of the Spasticity in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Spasticity in USD MM (2016-2028)
  • Table 42:7MM- Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Spasticity in USD MM (2016-2028)
  • Table 45: United States-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Spasticity in USD MM (2016-2028)
  • Table 48: Germany-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Spasticity in USD MM (2016-2028)
  • Table 51: France-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Spasticity in USD MM (2016-2028)
  • Table 54: Italy-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Spasticity in USD MM (2016-2028)
  • Table 57: Spain-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Spasticity in USD MM (2016-2028)
  • Table 60:UK-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Spasticity in USD MM (2016-2028)
  • Table 63: Japan-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Spasticity by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Spasticity in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Spasticity in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Spasticity in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Spasticity in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Spasticity in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Spasticity in United States (2016-2028)
  • Figure 7: Treatable Cases of the Spasticity in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Spasticity in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Spasticity in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Spasticity in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Spasticity in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Spasticity in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Spasticity in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Spasticity in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Spasticity in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Spasticity in France (2016-2028)
  • Figure 17: Treatable Cases of the Spasticity in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Spasticity in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Spasticity in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Spasticity in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Spasticity in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Spasticity in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Spasticity in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Spasticity in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Spasticity in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Spasticity in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Spasticity in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Spasticity in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Spasticity in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Spasticity in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Spasticity in UK (2016-2028)
  • Figure 32: Treatable Cases of the Spasticity in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Spasticity in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Spasticity in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Spasticity in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Spasticity in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Spasticity in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Spasticity in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 45: United States-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 51: France-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 60:UK-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
Back to Top